SYRE
NASDAQ
US
Spyre Therapeutics, Inc. - Common Stock
$47.58
▼ $-1.32
(-2.70%)
Vol 438K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$2.5B
ROE
-31.2%
Margin
-22158.5%
D/E
0.00
Beta
3.11
52W
$11–$35
Wall Street Consensus
21 analysts · Apr 202611
Strong Buy
9
Buy
1
Hold
0
Sell
0
Strong Sell
95.2%
Buy Rating
Price Chart
Similar Stocks
DNTH
Dianthus Therapeutics Inc
$1.8B
FOLD
Amicus Therapeutics Inc
$4.4B
VKTX
Viking Therapeutics Inc
$4.0B
ACAD
ACADIA Pharmaceuticals Inc
P/E 17.3
$4.5B
LEGN
Legend Biotech Corp
$4.0B
DNLI
Denali Therapeutics Inc
$2.6B
DYN
Dyne Therapeutics Inc
$3.2B
TNGX
Tango Therapeutics Inc
$1.2B
TWST
Twist Bioscience Corp
$1.9B
Earnings
Beat rate: 75.0%
Next Report
May 06, 2026
EPS Estimate: $-0.68
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.68 | — | — |
| Dec 2025 | $-0.79 | $-0.70 | +$0.09 |
| Sep 2025 | $-0.76 | $-0.15 | +$0.61 |
| Jun 2025 | $-0.77 | $-0.77 | $0.00 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -46.4% | -51.2% | -51.2% | -51.2% | -51.2% | -31.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -22158.5% | -22158.5% | -22158.5% | -22158.5% | -22158.5% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.49 | 6.49 | 6.49 | 6.49 | 10.90 | 10.98 |
Key Ratios
ROA (TTM)
-26.8%
P/S (TTM)
2066.60
P/B
2.6
EPS (TTM)
$-2.57
52W High
$35.31
52W Low
$10.91
$10.91
52-Week Range
$35.31
How does SYRE compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
SYRE valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2066.6
▲
15982%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
2.6
▲
7%
above
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
SYRE profitability vs Biotechnology peers
ROE
-31.2%
▲
54%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-22158.5%
▼
7627%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-26.8%
▲
43%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
SYRE financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
11.0
▲
147%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
3.1
▲
221%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
SYRE fundamentals radar
SYRE
Peer median
Industry
SYRE profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio